mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2015-3-30-32mrj-636Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSПрименение диацереина для лечения остеоартроза крупных суставов (обзор литературы и собственный опыт)Use of diacerein for the treatment of large joint osteoarthritis (A review of literature and the author’s own experience)БалабановаРимма МихайловнаBalabanovaRimma Mikhailovna

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115552

balabanova@irramn.ruФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201518092015933032Copyright © Балабанова Р.М., 20152015Балабанова Р.М.Balabanova R.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/636

Остеоартроз (ОА) является хроническим медленно прогрессирующим воспалительным заболеванием, в патогенезе которого большая роль отводится иммунным нарушениям – увеличению синтеза провоспалительных цитокинов (интерлейкин 1, фактор некроза опухоли α), активирующих катаболические процессы не только в хрящевой ткани, но и в субходральной кости и других структурах сустава. В качестве симптом-модифицирующей терапии, блокирующей образование простагландинов, рекомендуется прием нестероидных противовоспалительных препаратов. Выбор медленно действующих симптоматических препаратов достаточно широк. Одним из них является диацереин. Автор оценила эффективность и безопасность диацереина в лечении ОА коленных и тазобедренных суставов за 7-летний период. Представлен собственный опыт использования препарата.

Osteoarthritis is (OA) is a chronic slowly progressive inflammatory disease, in the pathogenesis of which a large role is assigned to immune disorders: increased synthesis of proinflammatory cytokines (interleukin 1, tumor necrosis factor-α) that activate catabolic processes not only in cartilaginous tissue, but also in subchondral bone and other joint structures. Nonsteroidal anti-inflammatory drugs are recommended to be used as symptom-modifying agents that block the production of prostaglandins. The choice of slowly symptomatic drugs is rather wide. Diacerein is one of them. The author has evaluated the efficacy and safety of diacerein in the treatment of knee and hip OA over a period of 7 years. She also presents her own experience in using the drug.

остеоартрознестероидные противовоспалительные препаратыдиацереинosteoarthritisnonsteroidal anti-inflammatory drugsdiacereinReferencesBijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011 Jun 18;377(9783):2115–26. doi: 10.1016/S0140-6736(11)60243-2.Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011 Jun 18;377(9783):2115–26. doi: 10.1016/S0140-6736(11)60243-2.Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symtoms of osteoarthritis. Nat Rev Rheumatol. 2010 Nov;6(11):625–35. doi: 10.1038/nrrheum.2010.159. Epub 2010 Oct 5.Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symtoms of osteoarthritis. Nat Rev Rheumatol. 2010 Nov;6(11):625–35. doi: 10.1038/nrrheum.2010.159. Epub 2010 Oct 5.Hochberg MC, Altman RD, April KT, et al. ACR 2012 recommendations for the use of nonfarmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465–74.Hochberg MC, Altman RD, April KT, et al. ACR 2012 recommendations for the use of nonfarmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465–74.Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–20.Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–20.Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J. 2006 Jul;27(14):1657–63. Epub 2006 May 26.Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J. 2006 Jul;27(14):1657–63. Epub 2006 May 26.Martel-Pelletier J, Mineau F, Jolicoeur FC, et al. In vitro effects of Diacerhein and Rhein on IL-1 and TNF-α system in human osteoarthritis synovium and chondrocytes. J Rheumatol. 1998 Apr;25(4):753–62.Martel-Pelletier J, Mineau F, Jolicoeur FC, et al. In vitro effects of Diacerhein and Rhein on IL-1 and TNF-α system in human osteoarthritis synovium and chondrocytes. J Rheumatol. 1998 Apr;25(4):753–62.Pelletier JP, Mineau F, Boileau C, MartelPelletier J. Diacerhein reduce the level of cartilagePelletier JP, Mineau F, Boileau C, MartelPelletier J. Diacerhein reduce the level of cartilagechondrocyte DNA fragmentation and death in experimental dog osteoarthritis cartilage at the same time that in inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol. 2003 Mar-Apr;21(2):171–7.chondrocyte DNA fragmentation and death in experimental dog osteoarthritis cartilage at the same time that in inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol. 2003 Mar-Apr;21(2):171–7.Malaguti C, Vilella CA, Vieira KP, et al Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol. 2008 Jun;8(6):782–91. doi: 10.1016/j.intimp.2008.01.020. Epub 2008 Feb 20.Malaguti C, Vilella CA, Vieira KP, et al Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol. 2008 Jun;8(6):782–91. doi: 10.1016/j.intimp.2008.01.020. Epub 2008 Feb 20.Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo-controlled study with primery end points at two months after the end of a threemonth treatment period. Arthritis Rheum. 2007 Dec;56(12):4055–64.Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo-controlled study with primery end points at two months after the end of a threemonth treatment period. Arthritis Rheum. 2007 Dec;56(12):4055–64.Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with Diacerhein in the treatment osteoarthritis. Arch Intern Med. 2006 Sep 25;166(17):1899–906.Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with Diacerhein in the treatment osteoarthritis. Arch Intern Med. 2006 Sep 25;166(17):1899–906.Leeb BF, Rintelen B. Systematic metaanalysis trials with Diacerhein in osteoarthritis. Osteoarth.Cartilage. 2005;13(Suppl.A):68.Leeb BF, Rintelen B. Systematic metaanalysis trials with Diacerhein in osteoarthritis. Osteoarth.Cartilage. 2005;13(Suppl.A):68.Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year, placebo-controlled trial. Arthritis Rheum. 2001 Nov;44(11):2539–47.Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year, placebo-controlled trial. Arthritis Rheum. 2001 Nov;44(11):2539–47.Каратеев АЕ. Достоинства и недостатки диацереина. Современная ревматология. 2014;8(4):90–5. [Karateev AE. Diacerein: Advantages and disadvantages. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4):90–5. (In Russ.)]. DOI: http//dx.doi.org/10.14412/2074-2711-2014-4-90-95Каратеев АЕ. Достоинства и недостатки диацереина. Современная ревматология. 2014;8(4):90–5. [Karateev AE. Diacerein: Advantages and disadvantages. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4):90–5. (In Russ.)]. DOI: http//dx.doi.org/10.14412/2074-2711-2014-4-90-95Витвицкая КБ, Калягин АН, Стельмах ЮЛ и др. Оценка эффективности диацереина (артрокера) у больных остеоартрозом различной локализации. Тезисы VII Всероссийской конференции ревматологов. Владимир; 2012. [Vitvitskaya KB, Kalyagin AN, Stel'makh YuL, et al. Evaluation of the effectiveness of diacerhein (artrocare) in patients with osteoarthritis of different localization. Abstracts of the VII all-Russian conference of rheumatologists. Vladimir; 2012. (In Russ.)].Витвицкая КБ, Калягин АН, Стельмах ЮЛ и др. Оценка эффективности диацереина (артрокера) у больных остеоартрозом различной локализации. Тезисы VII Всероссийской конференции ревматологов. Владимир; 2012. [Vitvitskaya KB, Kalyagin AN, Stel'makh YuL, et al. Evaluation of the effectiveness of diacerhein (artrocare) in patients with osteoarthritis of different localization. Abstracts of the VII all-Russian conference of rheumatologists. Vladimir; 2012. (In Russ.)].Заигрова НК. Оценка эффективности препарата артрокер при остеоартрозе коленных суставов. Современная ревматология. 2013;7(4):23–5. [Zaigrova NK. Evaluation of the efficacy of аrthrocare for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23–5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2013-2434.Заигрова НК. Оценка эффективности препарата артрокер при остеоартрозе коленных суставов. Современная ревматология. 2013;7(4):23–5. [Zaigrova NK. Evaluation of the efficacy of аrthrocare for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23–5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2013-2434.

The authors declare that there are no conflicts of interest present.